Value, Evidence, and Access: insights for markets outside of the EU5

Planning for access in smaller EU markets is often overlooked until after an asset is reimbursed in the major European markets.

Understanding the key considerations and evidentiary requirements ahead of time will support the development of a robust evidence package and aid launch sequence planning, to secure optimum market access across Europe. 

This report summarizes: 

  • health technology assessment and market access processes in several smaller EU markets: Bulgaria, the Czech Republic, Finland, the Netherlands, and Romania 

  • key considerations for manufacturers ahead of launch in these markets to drive operational excellence and secure timely, quality access 

  • how operational excellence and the PRMA Navigator® digital application can help maximize the likelihood of success in these markets. 

 

FREE eBook

Value, Evidence, and Access: insights for markets outside of the EU5

Latest insights

Driving BioPharma Access in Europe: Insights for ...

PRMA Consulting becomes Avalere Health, creating the ...

World Orphan Drug Congress 2023: solutions for market ...